secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2026-09-08T11:39:23+00:00
Accession:  0001193125-26-384386
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology appoints Thomas Civik as permanent CEO and Chairman; Flavin becomes Lead Independent Director
--------------------------------------------------------------------------------

- Civik, interim CEO since Feb 2026, named permanent CEO and Chairman effective Sept 4, 2026; Flavin transitions to Lead Independent Director.
- New CEO package: $710k base salary, 60% target bonus, $100k sign-on bonus, and option for 2,503,050 shares vesting over 4 years.
- Board member Santhosh Palani resigned Sept 4, 2026; board reduced from 8 to 7 members, with his unvested equity accelerated.
- Company expects updated MICVO Phase 1 monotherapy data in 2L+ R/M HNSCC in Fall 2026 and Phase 1/2 combo data with pembrolizumab in Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000119312526384386/0001193125-26-384386-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000119312526384386/pyxs-20260903.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-384386

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer